Business Context and Reporting Period
This Form 8-K was filed by FORM Holdings Corp. on September 8, 2016. The filing reports the entry into Amendment No. 1 to a previously announced Merger Agreement with XpresSpa Holdings, LLC. The amendment clarifies the stockholder approval threshold required for the proposed merger, under which FORM will acquire XpresSpa.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels for the reporting period. However, it details the financial consideration for the merger:
- Common Stock Consideration: 2,500,000 shares of FORM Common Stock.
- Preferred Stock Consideration: 494,792 shares of Series D Convertible Preferred Stock with an aggregate initial liquidation preference of $23,750,000, accruing dividends at 9% per annum.
- Warrant Consideration: Five-year warrants to purchase 2,500,000 shares of FORM Common Stock at an exercise price of $3.00 per share.
Material Changes
The primary material change is the execution of Amendment No. 1 to the Merger Agreement dated August 8, 2016. This amendment specifically clarifies the stockholder approval threshold necessary to approve the merger. No other material changes to financial position or operations are disclosed in this document.
Guidance, Outlook, and Risks
Outlook and Process: FORM intends to file a Registration Statement on Form S-4 containing a proxy statement/prospectus. Stockholders will be solicited to vote on the transaction. The filing includes a cautionary note regarding forward-looking statements, noting that actual results may differ due to various risks.
Risks and Contingencies: Key risks identified include:
- The potential inability to complete the proposed transaction.
- The inability to realize the potential value of the merger for equity holders.
- The inability to raise capital to fund operations and the business plan.
- The risk that FORM may not maintain its listing on the Nasdaq Capital Market post-merger.
Investor Verification Checklist
- Verify the specific stockholder approval threshold clarified in Amendment No. 1 (Exhibit 2.1).
- Monitor the filing of the Form S-4 proxy statement/prospectus for detailed risk factors and transaction terms.
- Confirm FORM's ability to maintain its Nasdaq Capital Market listing following the merger.
- Assess the dilution impact of the 2,500,000 common shares, 494,792 preferred shares, and 2,500,000 warrants issued to XpresSpa unitholders.